Hyderabad, India and Princeton, NJ, USA. Walk 26,2018—Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) reported today that it has launched PalonosetronHydrochloride Injection,0.25 mg (base)/5 mL, a remedial comparable non-specific variant of ALOXI®(palonosetron hydrochloride) Injection endorsed by the U.S. Nourishment and Drug Administration (USFDA).
The ALOXI® brand and bland had U.S. offers of around $446 million MAT for the latest a year finishing off in January 2018 according to IMS Health*.
Dr. Reddy’s Palonosetron Hydrochloride Injection is accessible in a quality of 0.25 mg/5 mL (free base) in a single-dose vial bundled in a container containing one vial.
ALOXI® is a trademark of Helsinn Healthcare SA.
*IMS National Sales Perspective: Retail and Non-Retail MAT January 2018
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offer a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com